PET FACILITY ID #: _______________________________________
REGISTRY CASE #: _______________________________________
PATIENT NAME: _______________________________________

Your patient had a PET scan on: mm/dd/yyyy.

You previously indicated that the PET scan was done for diagnosis of suspected osseous metastatic disease in a patient without a pathologic diagnosis of cancer.

- After reviewing the PET report, please complete the following questions and return the form to the PET Facility.
- This form must be entered into the database within 30 days of the PET scan.

1. IN LIGHT OF THE PET FINDINGS, WHAT IS YOUR CURRENT ASSESSMENT OF THE LIKELIHOOD OF OSSEOUS METASTATIC DISEASE?

☐ Definitely present
☐ Probably present
☐ Uncertain
☐ Probably not present
☐ Definitely not present

2. SINCE OBTAINING THE SCAN, HAS A TISSUE BIOPSY BEEN PERFORMED OF A SUSPICIOUS OSSEOUS SITE?

☐ Yes
☐ No

If yes, indicate whether the bone biopsy results are:

☐ Negative
☐ Positive
☐ Pending

3. HAS A PATHOLOGIC DIAGNOSIS OF CANCER BEEN CONFIRMED FROM ANY SITE?

☐ Yes
☐ No
4. DID THE PET SCAN ENABLE YOUR PATIENT TO AVOID ANY

   a. noninvasive diagnostic tests?
      □ Yes
      □ No

   b. any invasive procedures?
      □ Yes
      □ No

5. I HAVE READ THE REFERRING PHYSICIAN INFORMATION STATEMENT AND:

      □ I DO give my consent for the inclusion of data collected for this patient in NOPR research.
      □ I DO NOT give my consent for the inclusion of data collected for this patient in NOPR research.

6. NAME OF PERSON SUBMITTING THIS FORM

   First Name: __________________  Last Name: ______________________  Date: ___/___/___

7. PHYSICIAN ATTESTATION OF DATA ACCURACY

   By signing below I verify that, to the best of my knowledge, the information on this form is accurate.

   Physician Signature: ________________________________  Date: ___/___/___

   Printed Name of Physician: ________________________________

Thank you for your assistance.
Your patient had a PET scan on mm/dd/yyyy. [Date will automatically be filled.]

You previously indicated that the PET scan was done for initial staging of cancer type [Cancer type will automatically be filled in from data supplied on Pre-PET form.]

- After reviewing the PET report, please complete the following questions and return the form to the PET Facility.
- This form must be entered into the database within 30 days of the PET scan.

1. COMPARED TO YOUR PRE-PET ASSESSMENT, WHAT IS YOUR IMPRESSION OF THE EXTENT OF THE PATIENT'S CANCER?
   - More extensive
   - No change
   - Less extensive

2. DID THE PET SCAN ENABLE YOUR PATIENT TO AVOID ANY
   a. noninvasive diagnostic tests?  
      - Yes
      - No
   b. any invasive procedures?  
      - Yes
      - No

3. YOUR POST-PET WORKING CLINICAL SUMMARY STAGING IS? (You must check only one)
   - No evidence of disease / In remission
   - Localized only
   - Regional by direct extension
   - Metastatic (distant) with a single suspected site
   - Metastatic (distant) with multiple suspected sites
   - Unknown or uncertain
4. IN LIGHT OF THE PET FINDINGS, WHICH ONE OF THE FOLLOWING ARE YOU PLANNING OR HAVE YOU ALREADY DONE AS THE NEXT STEP IN YOUR CURRENT MANAGEMENT STRATEGY? (check only one)

☐ Observation (with close follow-up)

☐ Additional Imaging

If additional imaging is selected, please indicate which specific type of imaging you would order next. (check one)

☐ Plain radiographs
☐ Body CT (spine, neck, chest, and/or abdomen/pelvis)
☐ Extremity CT
☐ Body MRI (neck, chest, and/or abdomen/pelvis)
☐ Extremity MRI
☐ FDG-PET
☐ Other, specify: ______________________

☐ Tissue Biopsy (surgical, percutaneous, or endoscopic).
   [Note: If concurrent biopsy and a surgical procedure are planned, then mark “treatment” below.]

☐ Supportive care only (e.g., pain management, hospice care)

☐ Treatment for the Cancer
   If treatment was selected, answer the questions below:

   a. Treatment Goal: (check one)
      ☐ Curative
      ☐ Palliative

   b. Treatment will be directed to: (check all that apply)
      ☐ Primary tumor and/or locoregional disease
      ☐ Non-osseous distant metastatic disease
      ☐ Osseous distant metastatic disease
c. Type(s): (check all that apply)
   - Surgery
   - Radiation
   - Chemotherapy (including biologic modifiers)
   - Hormonal therapy
   - Bisphosphonate therapy
   - Immunotherapy (e.g., sipuleucel T (Provenge®) for prostate cancer)
   - Radiopharmaceutical therapy (strontium-89, samarium-153, etc.)
   - Other
   Specify other treatment type: _________________________________________

5. I HAVE READ THE REFERRING PHYSICIAN INFORMATION STATEMENT AND:
   - I DO give my consent for the inclusion of data collected for this patient in NOPR research.
   - I DO NOT give my consent for the inclusion of data collected for this patient in NOPR research.

6. NAME OF PERSON SUBMITTING THIS FORM
   First Name: ________________  Last Name: ___________________  Date: ____/____/____

7. PHYSICIAN ATTESTATION OF DATA ACCURACY
   By signing below I verify that, to the best of my knowledge, the information on this form is accurate.

   Physician Signature: ___________________________  Date: ____/____/____

   Printed Name of Physician: ___________________________

Thank you for your assistance.

PRA Disclosure Statement
According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0968. The time required to complete this information collection is estimated to average five (5) minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.
Your patient had a PET scan on mm/dd/yyyy. [Date will automatically be filled.]

You previously indicated that the PET scan was done for treatment response monitoring of cancer type [Will automatically be filled in from data supplied on Pre-PET form.] to chemo / radiation / or other therapy.

- After reviewing the PET report, please complete the following questions and return the form to the PET Facility.
- This form must be entered into the database within 30 days of the PET scan.

1. WHAT IS YOUR CURRENT IMPRESSION (IN LIGHT OF THE PET FINDINGS) OF YOUR PATIENT’S RESPONSE TO CURRENTLY ONGOING THERAPY? (CHECK ONE)?
   - Complete response
   - Partial response
   - No response (stable disease)
   - Progressive disease

2. IN LIGHT OF THE PET RESULTS, HOW HAS THE PROGNOSIS FOR YOUR PATIENT CHANGED? (CHECK ONE)
   - Better
   - No change
   - Worse

3. PLEASE INDICATE IF AND HOW YOU WILL MODIFY YOUR THERAPEUTIC PLAN IN LIGHT OF THE PET FINDINGS. (You must check only the one response that best characterizes your therapeutic plan)
   - Continue and complete currently ongoing therapy
   - Modify dose or schedule of currently ongoing therapy
   - Switch to another therapy or add another mode of therapy
   - Stop therapy and switch to supportive care
4. IN LIGHT OF THE PET FINDINGS, WHICH ONE OF THE FOLLOWING ARE YOU PLANNING OR HAVE YOU ALREADY DONE AS THE NEXT STEP IN YOUR CURRENT MANAGEMENT STRATEGY?

(check only one)

☐ Observation (with close follow-up)

☐ Additional Imaging

If additional imaging is selected, please indicate which specific type of imaging you would order next. (check one)

☐ Plain radiographs
☐ Body CT (spine, neck, chest, and/or abdomen/pelvis)
☐ Extremity CT
☐ Body MRI (neck, chest, and/or abdomen/pelvis)
☐ Extremity MRI
☐ FDG-PET

☐ Other, specify: ________________________

☐ Tissue Biopsy (surgical, percutaneous, or endoscopic).

[Note: If concurrent biopsy and a surgical procedure are planned, then mark “treatment” below.]

☐ Supportive care only (e.g., pain management, hospice care)

☐ Treatment for the Cancer

If treatment was selected, answer the questions below:

a. Treatment Goal: (check one)

☐ Curative
☐ Palliative

b. Treatment will be directed to: (check all that apply)

☐ Primary tumor and/or locoregional disease
☐ Non-osseous distant metastatic disease
☐ Osseous distant metastatic disease
c. **Type(s):** (check all that apply)
   - [ ] Surgery
   - [ ] Radiation
   - [ ] Chemotherapy (including biologic modifiers)
   - [ ] Hormonal therapy
   - [ ] Bisphosphonate therapy
   - [ ] Immunotherapy (e.g., sipuleucel T (Provenge®) for prostate cancer)
   - [ ] Radiopharmaceutical therapy (strontium-89, samarium-153, etc.)
   - [ ] Other
     Specify other treatment type: ________________________________

5. **DID THE PET SCAN ENABLE YOUR PATIENT TO AVOID ANY**
   a. noninvasive diagnostic tests?
      - [ ] Yes
      - [ ] No
   b. any invasive procedures?
      - [ ] Yes
      - [ ] No

6. **I HAVE READ THE REFERRING PHYSICIAN INFORMATION STATEMENT AND:**
   - [ ] I DO give my consent for the inclusion of data collected for this patient in NOPR research.
   - [ ] I DO NOT give my consent for the inclusion of data collected for this patient in NOPR research.

7. **NAME OF PERSON SUBMITTING THIS FORM**
   First Name: __________________  Last Name: __________________  Date: ______/_____/____

8. **PHYSICIAN ATTESTATION OF DATA ACCURACY**
   By signing below I verify that, to the best of my knowledge, the information on this form is accurate.
   Physician Signature: ________________________________  Date: ______/_____/____
   Printed Name of Physician: ________________________________

   Thank you for your assistance.
PRA Disclosure Statement

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0968. The time required to complete this information collection is estimated to average five (5) minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.
Your patient had a PET scan on mm/dd/yyyy. [Date will automatically be filled.]

You previously indicated that the PET scan was done for restaging of cancer type [Will automatically be filled in from data supplied on Pre-PET form.] to assess for

- new osseous metastatic disease as a site of recurrence or
- progression of known osseous metastatic disease.

[Reason will automatically be filled in from data supplied on Pre-PET form.]

After reviewing the PET report, please complete the following questions and return the form to the PET Facility.

This form must be entered into the database within 30 days of the PET scan.

1. COMPARED TO YOUR PRE-PET ASSESSMENT, WHAT IS YOUR IMPRESSION OF THE EXTENT OF THE PATIENT’S CANCER?

☐ More extensive
☐ No change
☐ Less extensive

2. YOUR POST-PET WORKING CLINICAL STAGING IS: (SELECT ONLY ONE)

☐ No evidence of disease / In remission
☐ Low probability of local recurrence or metastases
☐ Local recurrence
☐ Metastatic (distant) with a single suspected site
☐ Metastatic (distant) with a multiple suspected sites

3. DID THE PET SCAN ENABLE YOUR PATIENT TO AVOID ANY

   a. noninvasive diagnostic tests?

      ☐ Yes
      ☐ No

   b. any invasive procedures?

      ☐ Yes
      ☐ No
4. IN LIGHT OF THE PET FINDINGS, WHICH ONE OF THE FOLLOWING ARE YOU PLANNING OR HAVE YOU ALREADY DONE AS THE NEXT STEP IN YOUR CURRENT MANAGEMENT STRATEGY?  (check only one)

☐ Observation (with close follow-up)

☐ Additional Imaging
  If additional imaging is selected, please indicate which specific type of imaging you would order next. (check one)
  - Plain radiographs
  - Body CT (spine, neck, chest, and/or abdomen/pelvis)
  - Extremity CT
  - Body MRI (neck, chest, and/or abdomen/pelvis)
  - Extremity MRI
  - FDG-PET
  - Other, specify: _________________________

☐ Tissue Biopsy (surgical, percutaneous, or endoscopic).
  [Note: If concurrent biopsy and a surgical procedure are planned, then mark “treatment” below. ]

☐ Supportive care only (e.g., pain management, hospice care)

☐ Treatment for the Cancer

If treatment was selected, answer the questions below:

a. Treatment Goal: (check one)
  - Curative
  - Palliative

b. Treatment will be directed to: (check all that apply)
  - Primary tumor and/or locoregional disease
  - Non-osseous distant metastatic disease
  - Osseous distant metastatic disease
c. Type(s): (check all that apply)

- Surgery
- Radiation
- Chemotherapy (including biologic modifiers)
- Hormonal therapy
- Bisphosphonate therapy
- Immunotherapy (e.g., sipuleucel T (Provenge®) for prostate cancer)
- Radiopharmaceutical therapy (strontium-89, samarium-153, etc.)
- Other
  Specify other treatment type: __________________________

5. I HAVE READ THE REFERRING PHYSICIAN INFORMATION STATEMENT AND:

- I DO give my consent for the inclusion of data collected for this patient in NOPR research.
- I DO NOT give my consent for the inclusion of data collected for this patient in NOPR research.

6. NAME OF PERSON SUBMITTING THIS FORM

  First Name: ________________  Last Name: ___________________  Date: ____/____/____

7. PHYSICIAN ATTESTATION OF DATA ACCURACY

By signing below I verify that, to the best of my knowledge, the information on this form is accurate.

  Physician Signature: _____________________________  Date: ____/____/____
  Printed Name of Physician: ____________________________

Thank you for your assistance.

PRA Disclosure Statement

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0968. The time required to complete this information collection is estimated to average five (5) minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.